Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 565.29B |
| Revenue (ttm) | 43.32B |
| Net Income (ttm) | 9.82B |
| Shares Out | n/a |
| EPS (ttm) | 10.86 |
| PE Ratio | 57.58 |
| Forward PE | 31.10 |
| Dividend | 4.89 (0.79%) |
| Ex-Dividend Date | May 16, 2025 |
| Volume | n/a |
| Average Volume | 0 |
| Open | n/a |
| Previous Close | 620.00 |
| Day's Range | n/a |
| 52-Week Range | 540.00 - 823.96 |
| Beta | 0.33 |
| RSI | 48.30 |
| Earnings Date | Aug 7, 2025 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial numbers in USD Financial StatementsNews
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly's Zepbound
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's nonprofit acquires 23andMe.
Eli Lilly (LLY) Gains Canadian Approval for Crohn's Disease Drug Omvoh
Eli Lilly (LLY) Gains Canadian Approval for Crohn's Disease Drug Omvoh
How Do Investors Really Feel About Eli Lilly?
Eli Lilly's (NYSE: LLY) short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short , which is 0.97% of all regular shares ...
Eli Lilly: Still Too Pricey To Buy
Tech drives gains: NVDA and AMD lead the charge while healthcare faces setbacks
📈 Technology Sector: Bolstered by Semiconductors The technology sector has emerged as the standout performer today, with semiconductor stocks taking center stage. Nvidia (NVDA) is soaring with a rema...
Eli Lilly's Omvoh wins Health Canada approval for Crohn’s disease
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
Follow-Up: Sana Biotechnology 6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call In a public post in May, I wrote about Sana Biotechnology, Inc. (NASDAQ: SANA), a biotech that has d...
This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says
On CNBC's “ Mad Money Lightning Round ,” Jim Cramer said Rocket Lab Corporation (NASDAQ: RKLB) is a buy, adding that it is “one of the hottest stocks in the universe.” On June 30, the space-tech comp...
Lightning Round: Huntington Ingalls is a buy, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stocks including: Huntington Ingalls, Rocket Lab, Eli Lilly, TSS Inc, Conagra Brands, NXP Semiconductors, and more.
Market Whales and Their Recent Bets on LLY Options
Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE: LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...
Orr: PLTR & NVDA are Overvalued, GOOGL & LLY Great Upcoming Picks
Steven E. Orr finds Palantir (PLTR) overvalued right now and is looking for it to pull back to $100/share. He feels the same about Nvidia (NVDA), citing market FOMO.
Eli Lilly Has Seized the Lead in Anti-Obesity Drugs. Next Up: a Pill.
Eli Lilly Comes Out As ADA Winner
The Big 3: AVGO, LLY, UBER
Joe Tigay joins today's Big 3 and turns to three stocks that he believes investors should keep on their radar as the market "broadens." He talks about the potential for Broadcom (AVGO) to continue its...
This Is What Whales Are Betting On Eli Lilly
Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE: LLY), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...
Why dozens of Chinese firms are joining the weight loss drugs fray
Sales of weight-loss drugs in the West have soared in recent years, driven by the approval of a new class of more effective medication, the rapid growth in obese populations owing to poor diet and lac...
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
Eli Lilly and Co. (NYSE: LLY) is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $1...
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billi...
FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment
The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s (NYSE: LLY) Kisunla (donanemab-azbt) once-monthly amyl...
Eli Lilly granted FDA label update for Alzheimer’s drug Kisunla
US FDA approves gradual dosing for Lilly Alzheimer's drug
The U.S. Food and Drug Administration approved changing the prescribing information for Eli Lilly's Alzheimer's drug Kisunla to allow more gradual dosing to lower the risk of a potentially dangerous t...
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease
The newly recommended dosing schedule significantly lowered ARIA-E rates compared to the original dosing schedule, adding to the established safety profile of the treatment INDIANAPOLIS , July 9, 2025...
Trump threatens impose up to 200% tariff on pharmaceuticals 'very soon'
President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon." But he suggested that those levies would not go into effect immediately, saying h...
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
WW International, Inc. (WeightWatchers) (NASDAQ: WW) announced on Tuesday the successful completion of its strategic reorganization process. WeightWatchers implemented a financial reorganization tran...